Evidence map›Paper›PMID 41050192›Full record

ArticleSynthetic and systems biotechnology2026

Enhanced PrrAB system activation and restricted farnesyl pyrophosphate diversion underlie high coenzyme Q

Xinwei He, Huangwei Wang, Mindong Liang, Weishan Wang, Biqin Chen, Dan Li, Lixin Zhang, Gao-Yi Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Synthetic and systems biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinwei HeState Key Laboratory of Bioreactor Engineering and School of Biotechnology, East China University of Science and Technology, Shanghai, 200237, China.
Huangwei WangState Key Laboratory of Bioreactor Engineering and School of Biotechnology, East China University of Science and Technology, Shanghai, 200237, China.
Mindong LiangState Key Laboratory of Bioreactor Engineering and School of Biotechnology, East China University of Science and Technology, Shanghai, 200237, China.
Weishan WangState Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.
Biqin ChenInner Mongolia Kingdomway Pharmaceutical Co., Ltd, Hohhot, 010206, China.
Dan LiInner Mongolia Kingdomway Pharmaceutical Co., Ltd, Hohhot, 010206, China.
Lixin ZhangState Key Laboratory of Bioreactor Engineering and School of Biotechnology, East China University of Science and Technology, Shanghai, 200237, China.
Gao-Yi TanState Key Laboratory of Bioreactor Engineering and School of Biotechnology, East China University of Science and Technology, Shanghai, 200237, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The industrial

Indexed as

cbb3-type cytochrome c oxidaseCoenzyme Q10Farnesyl diphosphateInverse metabolic engineeringPrrAB systemRhodobacter sphaeroides

Identifiers

PMID41050192
PMCPMC12492659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.